RecruitingEarly Phase 1NCT04430517

Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia

Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia

Sponsor

Mclean Hospital

Enrollment

50 participants

Start Date

Mar 2, 2022

Study Type

INTERVENTIONAL

Conditions

Mild Cognitive Impairment Mild Alzheimer Disease

Summary

The primary aim of this study is to investigate the effects of exogenously administered nicotinamide riboside (NR) on brain energy metabolism, oxidative stress, and cognitive function in individuals with mild cognitive impairment (MCI) and mild Alzheimer's dementia (AD).

Eligibility

Min Age: 55 YearsMax Age: 89 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a supplement called nicotinamide riboside (a form of vitamin B3) can improve brain energy and reduce oxidative stress in people with mild cognitive impairment or early Alzheimer's disease. **You may be eligible if...** - You have been diagnosed with mild cognitive impairment or early Alzheimer's disease - You are able to understand and consent to taking part in the study - You are generally in stable health **You may NOT be eligible if...** - You have another serious neurological or medical condition affecting your cognition - You have an unstable mood or anxiety disorder in the last 6 months - You are currently taking certain medications that may interact with the supplement - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.